Stian Knappskog

Haukeland University Hospital — Norway

Biochemistry, Genetics and Molecular Biology · Life Sciences

52h-index32.8kcitations268works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(68), Epigenetics and DNA Methylation(49), Cancer-related Molecular Pathways(47), BRCA gene mutations in cancer(32), RNA modifications and cancer(19)

Publications221 total

Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas
International Journal of Cancer·2026Open Access
Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas.
Open Access CRIS of the University of Bern·2026Open Access
Neoadjuvant endocrine therapy with sequential palbociclib and chemotherapy based on Ki67 status in stage II-III breast cancer: An open-label, phase II study
The Breast·2025Open Access
471P Impact of TP53 and HRD status on 5-year survival in TNBC treated with sequential neoadjuvant olaparib and high-dose cyclophosphamide/carboplatin (the PETREMAC trial)
Annals of Oncology·2025
847P Molecular-clinical characteristics and treatment outcome for metastatic colorectal neuroendocrine carcinomas and adenocarcinomas: A comparison of two population-based prospective cohorts
Annals of Oncology·2025
Triple-Negative Breast Cancer on the Rise or…? [Letter]
Breast Cancer Targets and Therapy·2025Open Access
Abstract LB308: Rewiring of methylation during embryogenesis can seed cancer decades later
Cancer Research·2025
Comments on the paper “Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple‐negative breast cancer” by Y. Chen et al.
International Journal of Cancer·2025Open Access
Constitutional Epimutations: From Rare Events Toward Major Cancer Risk Factors?
JCO Precision Oncology·2025· 1 cited
Germline variants in <i>CDKN2A</i> wild‐type melanoma prone families
Molecular Oncology·2025Open Access
The impact of functional MDM2-polymorphisms on neutrophil counts in breast cancer patients during neoadjuvant chemotherapy
BMC Cancer·2025Open Access
MGMT epimutations and risk of incident cancer of the colon, glioblastoma multiforme, and diffuse large B cell lymphomas
Clinical Epigenetics·2025· 2 citedOpen Access
Author response for "Germline variants in &lt;i&gt;CDKN2A&lt;/i&gt; wild‐type melanoma prone families"
2025
Pancreatic neuroendocrine tumors and <i>MUTYH</i> pathogenic variants: a multinational study
Therapeutic Advances in Medical Oncology·2025· 2 citedOpen Access
Letter to the Editor in response to paper “BRCA1 promoter methylation in triple-negative breast cancer……” by K Daster et al
Breast Cancer Research and Treatment·2024
Interactions between neutrophils and macrophages harboring gram-negative bacteria promote obesity-associated breast cancer
2024Open Access
Germline variants in patients diagnosed with pediatric soft tissue sarcoma
Acta Oncologica·2024· 3 citedOpen Access
Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms
British Journal of Cancer·2024· 7 citedOpen Access
Abstract PO5-25-12: CDH1 mutations predict resistance to neoadjuvant taxane therapy
Cancer Research·2024· 1 cited
Abstract PS07-09: Prenatal BRCA1 epimutations is a major cause of triple-negative breast cancer
Cancer Research·2024
page 1 of 12Next →

Frequent Co-authors

Per Eystein Lønning(34), Serena Nik‐Zainal(10), Sancha Martin(10), Andrea L. Richardson(10), Christine Desmedt(9), Carlos Caldas(8), Helen Davies(8), Paul N. Span(8), Michael R. Stratton(8), Ludmil B. Alexandrov(7), David C. Wedge(7), Sunil R. Lakhani(7), Manasa Ramakrishna(7), Anne Vincent‐Salomon(7), John W.M. Martens(7), Anne‐Lise Børresen‐Dale(6), Jórunn E. Eyfjörd(6), Lucy Yates(6), Moritz Gerstung(6), Colin A. Purdie(6)